LSD for Anxiety: Single Dose Reduces GAD Symptoms – Phase 2b Results

Summary of the Article: LSD Shows promise in Treating Generalized Anxiety Disorder (GAD)

this article reports‍ on a groundbreaking,⁢ first-of-its-kind, randomized, placebo-controlled trial (MMED008) investigating the use of lysergic acid ⁢diethylamide‍ (LSD), specifically MM120 (lysergide D-tartrate), for the treatment of Generalized Anxiety Disorder (GAD). hear are the key takeaways:

Significant Anxiety reduction: A single dose of MM120 (100μg and 200μg) significantly reduced anxiety symptoms in adults ⁣wiht moderate⁢ to severe GAD,with improvements ⁢lasting up to 12 weeks.
Primary & Secondary Endpoints Met: The study ⁣successfully met both its primary‍ endpoint (dose-response relationship on the Hamilton⁣ Anxiety Rating Scale at week 4) and key secondary⁣ endpoint (significant symptom‍ improvement on the HAM-A scale).
optimal Dose: 100μg of MM120 was identified as the optimal dose, showing a 7.6-point greater ‍reduction in HAM-A scores compared to placebo at week 4.
High Response & Remission Rates: Participants receiving 100μg of ⁣MM120 had a 65% clinical response rate‍ and⁤ a ⁢48% clinical remission rate sustained through week 12.
Broader Improvements: The study also showed improvements⁣ in clinician-rated disease severity (CGI-S), depression symptoms (MADRS), functional disability, and quality of life.
Unmet Need: This research is especially important as there haven’t been any new FDA-approved medications for GAD since 2007, and a significant portion of patients don’t respond to existing treatments.
No Psychotherapy: Notably, the treatment was administered without* any accompanying psychotherapeutic intervention.

The investigators ⁤believe these results represent a potential paradigm⁢ shift in the treatment ⁣of GAD and highlight the promise of psychedelics in psychiatric medicine.